Loading...
Loading...
FOLD| Name | Value |
|---|---|
| Revenues | 88.1M |
| Cost of Revenue | 9.4M |
| Gross Profit | 78.7M |
| Operating Expense | 119.5M |
| Operating I/L | -40.7M |
| Other Income/Expense | -29.3M |
| Interest Income | 2.0M |
| Pretax | -70.1M |
| Income Tax Expense | -14.2M |
| Net Income/Loss | -55.9M |
Amicus Therapeutics, Inc. is a biotechnology company specializing in developing and commercializing precision medicines for rare diseases. Its flagship product, Galafold, is an oral medication for adults with Fabry disease. The company also focuses on developing AT-GAA for Pompe disease and enzyme replacement therapies. Additionally, it is conducting clinical studies for gene therapies targeting CLN3 and CDKL5. Amicus Therapeutics generates revenue through the sales of Galafold and potential future commercialization of its pipeline products, as well as through collaboration and license agreements with research institutions and pharmaceutical companies.
